Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. [electronic resource]
Producer: 20110414Description: 550-64 p. digitalISSN:- 1942-0870
- Animals
- Antibodies, Monoclonal -- chemistry
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- chemistry
- Cell Line, Tumor
- Clinical Trials as Topic
- Colonic Neoplasms -- drug therapy
- Female
- HT29 Cells
- Humans
- Immunoconjugates -- chemistry
- Indium Radioisotopes -- administration & dosage
- Injections, Intraperitoneal
- Injections, Intravenous
- Isothiocyanates -- chemistry
- Male
- Melanoma -- drug therapy
- Mice
- Mice, Nude
- Ovarian Neoplasms -- drug therapy
- Pentetic Acid -- analogs & derivatives
- Positron-Emission Tomography
- Prostatic Neoplasms -- drug therapy
- Radionuclide Imaging
- Receptor, ErbB-2 -- antagonists & inhibitors
- Tissue Distribution
- Trastuzumab
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
There are no comments on this title.
Log in to your account to post a comment.